JP2013532141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532141A5 JP2013532141A5 JP2013513412A JP2013513412A JP2013532141A5 JP 2013532141 A5 JP2013532141 A5 JP 2013532141A5 JP 2013513412 A JP2013513412 A JP 2013513412A JP 2013513412 A JP2013513412 A JP 2013513412A JP 2013532141 A5 JP2013532141 A5 JP 2013532141A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mir
- seq
- composition according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 5
- 229920000272 Oligonucleotide Polymers 0.000 claims 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000006011 modification reaction Methods 0.000 claims 4
- 230000000051 modifying Effects 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000004129 fatty acid metabolism Effects 0.000 claims 3
- 208000008466 Metabolic Disease Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 201000005603 Fabry disease Diseases 0.000 claims 1
- 206010018048 Gaucher's disease Diseases 0.000 claims 1
- 208000007345 Glycogen Storage Disease Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 102100014415 LIPA Human genes 0.000 claims 1
- 101700071157 LIPA Proteins 0.000 claims 1
- 208000005548 Medium chain acyl CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 206010072654 Medium-chain acyl-coenzyme A dehydrogenase deficiency Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 210000004413 Myocytes, Cardiac Anatomy 0.000 claims 1
- 208000006660 Niemann-Pick Disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010053687 Wolman's disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 210000002317 cardiac myocyte Anatomy 0.000 claims 1
- 201000008053 cholesterol ester storage disease Diseases 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000000229 preadipocyte Anatomy 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (20)
- 治療または予防の必要な被験体において、病的心肥大、心臓リモデリング、心筋梗塞、または心不全を治療または予防するための医薬組成物であって、miR−378および/またはmiR−378*の発現または活性の阻害剤を含む医薬組成物。
- 前記医薬組成物が、皮内、皮下、筋肉内、腹腔内、もしくは静脈内投与経路による投与、または心臓組織中への直接注射による投与のために調製される、請求項1に記載の医薬組成物。
- 治療または予防の必要な被験体の代謝障害を治療または予防するための医薬組成物であって、miR−378および/またはmiR−378*の発現または活性の阻害剤を含む医薬組成物。
- 前記代謝障害が、メタボリック症候群、肥満症、糖尿病、糖尿病性腎症、インスリン抵抗性、アテローム硬化症、脂質蓄積障害、糖原病、中鎖アシル−補酵素Aデヒドロゲナーゼ欠損、または異常なグルコース取込みおよび/もしくは利用である、請求項3に記載の医薬組成物。
- 前記脂質蓄積障害が、ニーマン・ピック病、ゴーシェ病、ファーバー病、ファブリ病、ウォルマン病、およびコレステリルエステル蓄積症からなる群から選択される、請求項4に記載の医薬組成物。
- 被験体の脂肪酸代謝を調節するための医薬組成物であって、miR−378および/またはmiR−378*の発現または活性のモジュレーターを含む医薬組成物。
- 前記モジュレーターがmiR−378および/またはmiR−378*の発現または活性の阻害剤である、請求項6に記載の医薬組成物。
- 脂肪酸代謝が増大する、請求項7に記載の医薬組成物。
- 前記miR−378および/またはmiR−378*の阻害剤がアンチセンスオリゴヌクレオチドである、請求項1、3または7に記載の医薬組成物。
- 前記アンチセンスオリゴヌクレオチドが、miR−378および/またはmiR−378*の成熟配列に少なくとも部分的に相補的な配列を含む、請求項9に記載の医薬組成物。
- 前記アンチセンスオリゴヌクレオチドが少なくとも1つの糖修飾および/または骨格修飾を含む、請求項10に記載の医薬組成物。
- 前記糖修飾がロックド核酸である、請求項11に記載の医薬組成物。
- 前記骨格修飾がホスホロチオエート結合である、請求項11に記載の医薬組成物。
- 前記アンチセンスオリゴヌクレオチドが約7〜約18ヌクレオチド長である、請求項10に記載の医薬組成物。
- 前記モジュレーターがmiR−378および/またはmiR−378*の発現または活性のアゴニストである、請求項6に記載の医薬組成物。
- 脂肪酸代謝が、前記miR−378および/またはmiR−378*アゴニストとの接触後の細胞において、前記アゴニストに暴露されなかった細胞と比較して、増大する、請求項15に記載の医薬組成物。
- 前記アゴニストがmiR−378および/またはmiR−378*の成熟配列を含むポリヌクレオチドである、請求項15に記載の医薬組成物。
- 前記細胞が、心筋細胞、骨格筋細胞、前脂肪細胞、または脂肪細胞である、請求項6に記載の医薬組成物。
- 前記アンチセンスオリゴヌクレオチドが、配列番号7、配列番号8、配列番号9、配列番号10、配列番号11、配列番号12、配列番号13、配列番号14、配列番号15、配列番号16、配列番号17、配列番号18、配列番号19、配列番号20、配列番号21、および配列番号22からなる群から選択される配列を有する、請求項10に記載の医薬組成物。
- 前記医薬組成物が、皮内、皮下、筋肉内、腹腔内、もしくは静脈内投与経路による投与のために調製される、請求項3または6に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35168310P | 2010-06-04 | 2010-06-04 | |
US61/351,683 | 2010-06-04 | ||
PCT/US2011/039308 WO2011153542A2 (en) | 2010-06-04 | 2011-06-06 | Regulation of metabolism by mir-378 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013532141A JP2013532141A (ja) | 2013-08-15 |
JP2013532141A5 true JP2013532141A5 (ja) | 2014-07-24 |
JP6109069B2 JP6109069B2 (ja) | 2017-04-05 |
Family
ID=45067341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013513412A Expired - Fee Related JP6109069B2 (ja) | 2010-06-04 | 2011-06-06 | miR−378による代謝調節 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8716258B2 (ja) |
EP (1) | EP2576785A4 (ja) |
JP (1) | JP6109069B2 (ja) |
CN (1) | CN103038349B (ja) |
AU (1) | AU2011261213B2 (ja) |
CA (1) | CA2801342A1 (ja) |
RU (1) | RU2585491C2 (ja) |
WO (1) | WO2011153542A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2580328A2 (en) * | 2010-06-11 | 2013-04-17 | Cellartis AB | Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
WO2012145374A1 (en) * | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
EP2763703B1 (en) * | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
CA2871073A1 (en) * | 2012-04-20 | 2013-10-24 | Aptamir Therapeutics, Inc. | Mirna modulators of thermogenesis |
WO2014145356A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
WO2015123672A2 (en) * | 2014-02-14 | 2015-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods for treating liver injury |
CN104027819B (zh) * | 2014-05-05 | 2016-09-14 | 烟台毓璜顶医院 | miR-509-3p表达抑制剂在制备治疗多囊卵巢综合征药物中的应用 |
CN105617399B (zh) * | 2014-11-04 | 2019-05-10 | 中国科学院上海生命科学研究院 | miRNA-378在脂肪肝治疗中的应用 |
CN105435247A (zh) * | 2015-12-31 | 2016-03-30 | 中国医学科学院基础医学研究所 | miR-378在预防和/或治疗肥胖症中的用途 |
CN108998514B (zh) * | 2018-08-20 | 2022-02-01 | 青岛大学 | miRNA-378及其抑制剂的应用和应用其的产品 |
WO2021020412A1 (ja) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Murf1を標的とする核酸医薬 |
CN114788866B (zh) * | 2021-01-25 | 2023-09-29 | 中国科学院上海营养与健康研究所 | Mafg作为胆固醇稳态调控靶点的应用及其调控剂 |
CN114788865B (zh) * | 2021-01-25 | 2023-09-01 | 中国科学院上海营养与健康研究所 | miR-378作为胆固醇稳态调控靶点的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928219B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA) |
EP1605978B1 (en) | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
EP2322665A1 (en) | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
DK1833840T3 (da) * | 2004-11-09 | 2010-10-18 | Santaris Pharma As | Micromirs |
EP2281888B1 (en) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
JP5173793B2 (ja) | 2005-04-29 | 2013-04-03 | ザ ロックフェラー ユニバーシティ | マイクロrna及びそれを阻害する方法 |
CA2625731A1 (en) | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in hiv genome and a method of identification thereof |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ, インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
US20100088775A1 (en) | 2006-05-26 | 2010-04-08 | Medvet Science Pty. Ltd. | Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same |
CA2681568C (en) | 2006-11-23 | 2019-01-08 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US9353368B2 (en) | 2007-05-23 | 2016-05-31 | Ge Healthcare Dharmacon, Inc. | Micro-RNA scaffolds and non-naturally occurring micro-RNAs |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
CN101821390A (zh) | 2007-06-14 | 2010-09-01 | 米尔克斯治疗有限责任公司 | 用于调节靶rna活性的寡核苷酸 |
WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
ES2575868T3 (es) | 2007-09-14 | 2016-07-01 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y sus usos |
WO2009044899A1 (ja) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | 細胞の増殖を制御する核酸 |
ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
WO2009058907A2 (en) * | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
CN101424640B (zh) | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
CA3069576A1 (en) | 2008-01-09 | 2009-07-16 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
US20110160285A1 (en) | 2008-03-13 | 2011-06-30 | The Regents Of The University Of Colorado | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
AU2009256243A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
US20110152352A1 (en) | 2008-06-10 | 2011-06-23 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
WO2010003420A2 (en) | 2008-06-17 | 2010-01-14 | Gentofte Hospital | Treatment of psoriasis and related diseases by mirna modulation |
CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
US9096850B2 (en) | 2009-08-24 | 2015-08-04 | Sirna Therapeutics, Inc. | Segmented micro RNA mimetics |
EP2475372B2 (en) | 2009-09-10 | 2020-10-21 | Velin-Pharma A/S | Method for the preparation of micro-rna and its therapeutic application |
EP2580328A2 (en) | 2010-06-11 | 2013-04-17 | Cellartis AB | Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
EP2446929A1 (en) | 2010-10-27 | 2012-05-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Microvesicles derived from atheroprotective endothelial cells for the treatment and prevention of atherosclerotic diseases |
WO2012145374A1 (en) | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
-
2011
- 2011-06-06 EP EP11790545.5A patent/EP2576785A4/en not_active Withdrawn
- 2011-06-06 CA CA2801342A patent/CA2801342A1/en not_active Abandoned
- 2011-06-06 WO PCT/US2011/039308 patent/WO2011153542A2/en active Application Filing
- 2011-06-06 US US13/702,033 patent/US8716258B2/en active Active
- 2011-06-06 CN CN201180038263.6A patent/CN103038349B/zh not_active Expired - Fee Related
- 2011-06-06 JP JP2013513412A patent/JP6109069B2/ja not_active Expired - Fee Related
- 2011-06-06 RU RU2013100002/10A patent/RU2585491C2/ru not_active IP Right Cessation
- 2011-06-06 AU AU2011261213A patent/AU2011261213B2/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013532141A5 (ja) | ||
JP2014530222A5 (ja) | ||
RU2013100002A (ru) | РЕГУЛЯЦИЯ МЕТАБОЛИЗМА С ПОМОЩЬЮ MiR-378 | |
RU2011151991A (ru) | Идентификация микро-рнк, учавствующих в постинфарктном ремоделировании и сердечной недостаточности | |
Kraniou et al. | Acute exercise and GLUT4 expression in human skeletal muscle: influence of exercise intensity | |
Raher et al. | A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload | |
Sørensen et al. | Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice | |
JP2013514372A5 (ja) | ||
Chaturvedi et al. | Epigenetic mechanisms underlying cardiac degeneration and regeneration | |
US9163235B2 (en) | Inhibitors of the miR-15 family of micro-RNAs | |
JP2012516856A5 (ja) | ||
HRP20130766T1 (hr) | Mikrornk (mirnk) mir-21 za dijagnostiäśke i terapijske svrhe | |
JP2012050438A5 (ja) | ||
JP2012050439A5 (ja) | ||
US20120184596A1 (en) | Microrna inhibitors comprising locked nucleotides | |
JP2014503192A5 (ja) | ||
JP2016512205A5 (ja) | ||
Nelson et al. | Increase in cardiac myosin heavy-chain (MyHC) alpha protein isoform in hibernating ground squirrels, with echocardiographic visualization of ventricular wall hypertrophy and prolonged contraction | |
WO2010057045A3 (en) | Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo | |
Stadnik et al. | Clinical aspects of the use of trimetazidine in the prevention and treatment of myocardial diseases | |
Wiggers et al. | Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium | |
Ovchinnikov et al. | Blunted functional responses to pre-and postjunctional sympathetic stimulation in hibernating myocardium | |
Gui et al. | Cardiac regeneration: 20 years of development and update in zebrafish and mouse | |
WANG et al. | NAC on the improvement of insulin resistance induced by FFA in rats | |
Gui-rong et al. | The influence of high glucose circumstance on proliferating cycle of MG63 cell and expression of correlated factors. |